Rosuvastatin in Older Patients with Systolic Heart Failure
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients. METHODS: A total of 5011 patients at least 60 years of age with New York Heart Association class II, III, or IV ischemic, systolic heart failure were randomly assigned to receive 10 mg of rosuvastatin or placebo per day. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary outcomes included death from any cause, any coronary event, death from cardiovascular causes, and the number of hospitalizations. RESULTS: As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-density lipoprotein cholesterol (difference between groups, 45.0%; P<0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P<0.001). During a median follow-up of 32.8 months, the primary outcome occurred in 692 patients in the rosuvastatin group and 732 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.83 to 1.02; P=0.12), and 728 patients and 759 patients, respectively, died (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.31). There were no significant differences between the two groups in the coronary outcome or death from cardiovascular causes. In a prespecified secondary analysis, there were fewer hospitalizations for cardiovascular causes in the rosuvastatin group (2193) than in the placebo group (2564) (P<0.001). No excessive episodes of muscle-related or other adverse events occurred in the rosuvastatin group. CONCLUSIONS: Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations. The drug did not cause safety problems. (ClinicalTrials.gov number, NCT00206310.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The clinical benefit of adding ezetimibe was consistent across patient subgroups [299,444] and also led to a reduction of total CV events [445], stroke [446], and rehospitalizations [447].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [445]
In the citing paper
“The Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) and Gruppo Italiano per lo Studio della Sopravivenza nell'Infarto Miocardico-Effect of Rosuvastatin in Patients with Chronic Heart Failure (GISSI-HF) trials in patients with symptomatic HF did not demonstrate any benefit on CV mortality and non-fatal MI and stroke, in spite of a marked reduction of LDL-C and hs-CRP.36,39”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [36]
In the citing paper
“In two large RCTs 373,374 there was no benefit on hard endpoints, such as CV mortality and non-fatal MI and stroke, in spite of a decrease in hospitalizations 373,375 and a marked reduction of LDL-C and hs-CRP in patients with mainly systolic heart failure.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [373]
In the citing paper
“Trials of low‐dose anticoagulation, 4 PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, 5 as well as statins 2 , 6 in patients with HF have been disappointing to date”
From Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT (2022) · cites this paper as [2]
In the citing paper
“Patients with heart failure (HF) are at high risk for atherosclerotic cardiovascular disease (ASCVD), 1 , 2 as designated by professional society guidelines. 3”
From Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT (2022) · cites this paper as [2]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Self-citationSacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Hjalmarson, Å., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vítovec, J., Aldershvile, J., et al. (2000) · JAMA · doi:10.1001/jama.283.10.1295 · Cited by 1,399
Self-citationThe Role of Coenzyme Q10 in Statin-Associated Myopathy
Marcoff, L., & Thompson, P. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.049 · Cited by 537
The endotoxin-lipoprotein hypothesis
Rauchhaus, M., Coats, A. J., & Anker, S. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02690-8 · Cited by 533
The relationship between cholesterol and survival in patients with chronic heart failure
Rauchhaus, M., Clark, A. L., Doehner, W., Davos, C., Bolger, A., Sharma, R., Coats, A. J. S., & Anker, S. D. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.016 · Cited by 444
Inhalation of levomepromazine in severe acute asthma
Pedersen, J. E., Olsen, A., & Banning, A. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91755-8 · Cited by 390
Cited by
Items 501–600 of 1,000
Charach, G., Rabinovich, A., Argov, O., Wexler, D., Sheps, D. S., Charach, L., Weintraub, M. S., & George, J. (2013) · Cardiology · doi:10.1159/000355164 · Cited by 29
Atherosclerotic cardiovascular disease risk and evidence-based management of cholesterol
Roy, S. (2014) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.132916 · Cited by 33
Zhao, Q., Li, J., Yang, J., & Li, R. (2017) · Medicine · doi:10.1097/md.0000000000006094 · Cited by 29
Cleland, J. G. F., Coletta, A. P., Clark, A. L., & Cullington, D. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp071 · Cited by 32
Self-citationExploring new indications for statins beyond atherosclerosis: Successes and setbacks
Waters, D. D. (2010) · Journal of Cardiology · doi:10.1016/j.jjcc.2009.12.003 · Cited by 33
Kajinami, K., & Yasusyuki, K. (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s13492 · Cited by 31
Bertoluci, M. C., Netto, A. P., Pires, A. C., Pesaro, A. E. P., Schaan, B. D., Caramelli, B., Polanczyk, C. A., Junior, C. V. S., Gualandro, D. M., Malerbi, D. A. C., et al. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-58 · Cited by 34
Haver, V. G., Leach, I. M., KJEKSHUS, J. K., Fox, J. C., Wedel, H., Wikstrand, J., de Boer, R. A., van Gilst, W. H., McMurray, J. J. V., van Veldhuisen, D. J., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.237 · Cited by 28
Self-citationHeart Failure Due to Reduced Ejection Fraction: Medical Management.
Chavey, W. E., Hogikyan, R. V., Harrison, R. V., & Nicklas, J. M. (2017) · PubMed · Cited by 26
Laleman, N., Henrard, S., van den Akker, M., Goderis, G., Buntinx, F., Pottelbergh, G. V., & Vaes, B. (2018) · BMC Cardiovascular Disorders · doi:10.1186/s12872-018-0941-y · Cited by 32
NHG-Standaard Hartfalen: Tweede herziening
Hoes, A. W., Voors, A., Rutten, F. H., van Lieshout, J., Janssen, P. G. H., & Walma, E. (2011) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-8279-8_24 · Cited by 29
Lung capillary injury and repair in left heart disease: a new target for therapy?
Azarbar, S., & Dupuis, J. (2014) · Clinical Science · doi:10.1042/cs20130296 · Cited by 28
Therapeutic strategy for atherosclerosis based on bone-vascular axis hypothesis
Kim, J., Lee, W. S., & Kim, J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107436 · Cited by 29
Statins for Ischemic Systolic Heart Failure
Masoudi, F. A. (2007) · New England Journal of Medicine · doi:10.1056/nejme0707221 · Cited by 29
Tang, W. H. W., Shrestha, K. L., Troughton, R. W., Borowski, A. G., & Klein, A. L. (2011) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2011.00221.x · Cited by 27
Clinical evidence of statin therapy in non-dyslipidemic disorders
Ferri, N., & Corsini, A. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.02.003 · Cited by 31
“CORONA [73,79]”
BackgroundHuxley, R., Barzi, F., Woo, J., Giles, G. G., Lam, T. H., Rahimi, K., Konety, S., Ohkubo, T., Jee, S. H., Fang, X., et al. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-61 · Cited by 29
Shifting views on lipid lowering therapy
Krumholz, H. M., & Hayward, R. A. (2010) · BMJ · doi:10.1136/bmj.c3531 · Cited by 26
Statin-Associated Incident Diabetes: A Literature Review
Park, Z. H., Juska, A., Dyakov, D., & Patel, R. V. (2014) · The Consultant Pharmacist · doi:10.4140/tcp.n.2014.317 · Cited by 33
Effects of Lipophilic Statins for Heart Failure: A Meta-analysis of 13 Randomised Controlled Trials
Liu, G., Zheng, X., Xu, Y.-L., Lü, J., Hui, R., & Huang, X. (2014) · Heart Lung and Circulation · doi:10.1016/j.hlc.2014.05.005 · Cited by 30
“However, two largescale RCTs challenge these findings [8,9].”
BackgroundMultiple cytokine biomarkers in heart failure
Vistnes, M., Christensen, G., & Omland, T. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.3 · Cited by 28
Abdelhamid, M., Rosano, G. M. C., Metra, M., Adamopoulos, S. N., Böhm, M., Chioncel, O. D., Filippatos, G. S., Jankowska, E. A., Lopatin, Y. M., Lund, L. H., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2594 · Cited by 32
Self-citationUse of antidepressants and statins and short-term risk of new-onset diabetes among high risk adults
Bhattacharya, R., Ajmera, M., Bhattacharjee, S., & Sambamoorthi, U. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.04.016 · Cited by 28
“[63] Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JGF, Cornel JH, et al.”
BackgroundStatins in heart failure: do we need another trial?
Kadirvelu, A., Osei, & Reidpath, D. D. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s44499 · Cited by 29
Strandberg, T. E., Holme, I., Færgeman, O., Kastelein, J. J. P., Lindahl, C., Larsen, M. L., OLSSON, A. G., Pedersen, T. R., & Tikkanen, M. J. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.01.377 · Cited by 27
“In contrast to SCOT-LLA, the CORONA trial investigated older paients (average age 72 years) with established moderate to evere HF due to an ischemic cause (63% with NYHA class II or IV).(9) Patients were randomized to receive rosuvastatin r placebo for a median follow-up of 3 years.”
BackgroundMethodAbbas, A., Milles, J. J., & Ramachandran, S. (2012) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s7591 · Cited by 34
Badar, A., Moreno, A. C. P., Jhund, P. S., Wong, C. M., Hawkins, N. M., Cleland, J. G. F., van Veldhuisen, D. J., Wikstrand, J., KJEKSHUS, J. K., Wedel, H., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu342 · Cited by 27
“8 months and rosuvastatin did not reduce the riskof the primary composite outcome of death from cardiovascular (CV) causes, non-fatal MI, or nonfatal stroke.(6,7) Investigators recorded a history of ‘past or current angina’ in the case report form at the time of enrolment using a checkbox system.”
MethodSelf-citationImmune Modulation in Heart Failure: Past Challenges and Future Hopes
Flores‐Arredondo, J. H., García‐Rivas, G., & Torre‐Amione, G. (2011) · Current Heart Failure Reports · doi:10.1007/s11897-010-0044-2 · Cited by 27
“The abundance of potential beneficial effects in patients with HF led to a large randomized clinical trial in HF aimed to define an effect in the progression of HF. Unfortunately, CORONA and GISSI-HF failed to demonstrate conclusive clinical benefits when statins where used in patients with HF [ 60 , 61].”
BackgroundLee, M. S., Duan, L., Clare, R., Hekimian, A., Spencer, H. T., & Chen, W. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.04.027 · Cited by 30
The Cholesterol Paradox Revisited: Heart Failure, Systemic Inflammation, and Beyond
von Haehling, S., Schefold, J. C., Springer, J., & Anker, S. D. (2008) · Heart Failure Clinics · doi:10.1016/j.hfc.2008.01.009 · Cited by 29
Lainščak, M., & Anker, S. D. (2009) · Herz · doi:10.1007/s00059-009-3211-z · Cited by 29
“The scrutiny of randomized trials, however, rejected the hypothesis of statin-associated mortality benefit in CORONA [ 39 ] and GISSI-HF [40] trials which included > 10,000 patients.”
ResultLandscape of Statin as a Cornerstone in Atherosclerotic Cardiovascular Disease
Yang, C., Wu, Y., Qian, J., & Li, J. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2412373 · Cited by 31
Askevold, E. T., Gullestad, L. L., Nymo, S. H., KJEKSHUS, J. K., Yndestad, A., Latini, R., Cleland, J. G. F., McMurray, J. J. V., Aukrust, P., & Ueland, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133970 · Cited by 26
Self-citationZhong, P., Wu, D., Ye, X., Wu, Y., Li, T., Tong, S., & Liu, X. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s135785 · Cited by 29
Takada, T., Jujo, K., Inagaki, K., Abe, T., Kishihara, M., Shirotani, S., Endo, N., Watanabe, S., Suzuki, K., Minami, Y., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13629 · Cited by 29
Ma, W., Pan, Q., Pan, D., Xu, T., Zhu, H., & Li, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.713007 · Cited by 31
HFA-PEFF scores: prognostic value in heart failure with preserved left ventricular ejection fraction
Egashira, K., Sueta, D., Komorita, T., Yamamoto, E., Usuku, H., Tokitsu, T., Fujisue, K., Nishihara, T., Oike, F., Takae, M., et al. (2021) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2021.272 · Cited by 34
Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation
Kondo, T., Abdul‐Rahim, A. H., Talebi, A., Abraham, W. T., Desai, A. S., Dickstein, K., Inzucchi, S. E., Køber, L., Kosiborod, M., Martínez, F. A., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac487 · Cited by 30
Self-citationInflammation and Heart Failure: Searching for the Enemy—Reaching the Entelechy
PARASKEVAIDIS, I. A., Farmakis, D. T., Papingiotis, G., & Tsougos, E. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10010019 · Cited by 28
D’Amario, D., Laborante, R., Bianchini, E., Galli, M., Ciliberti, G., Mennuni, M. G., & Patti, G. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.131219 · Cited by 32
Approach to the diagnosis and management of lipoprotein disorders
Al-Waili, K., Al‐Rasadi, K., Awan, Z. A., & Genest, J. J. (2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328329135a · Cited by 27
Brooks, J. M., Cook, E. A., Chapman, C. G., Kulchaitanaroaj, P., Chrischilles, E. A., Welch, S., & Robinson, J. G. (2014) · Medical Care · doi:10.1097/mlr.0b013e3182a7fc3d · Cited by 29
Mitochondrial Therapies in Heart Failure
von Hardenberg, A., & Maack, C. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_123 · Cited by 27
Statins, ACE inhibitors and ARBs in cardiovascular disease
Montecucco, F., & Mach, F. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.12.003 · Cited by 28
Self-citationMentz, R. J., Allen, B. D., Kwasny, M., Konstam, M. A., Udelson, J. E., Ambrosy, A. P., Fought, A. J., Vaduganathan, M., O’Connor, C. M., Zannad, F. M., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs139 · Cited by 26
Statin Use in Older Adults with Stable Atherosclerotic Cardiovascular Disease
Spencer‐Bonilla, G., Chung, S., Sarraju, A., Heidenreich, P. A., Palaniappan, L. P., & Rodríguez, F. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16975 · Cited by 26
Dyslipidemia: A Narrative Review on Pharmacotherapy
de Oliveira, L. D., de Assis, A. C. R., Giraldez, V. Z. R., Scudeler, T. L., & Soares, P. R. (2024) · Pharmaceuticals · doi:10.3390/ph17030289 · Cited by 30
Heart Failure With Preserved Ejection Fraction
Desai, A. S. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.03.075 · Cited by 30
Statins as Anti‐Arrhythmics: A Systematic Review Part II: Effects on Risk of Ventricular Arrhythmias
Abuissa, H. S., O’Keefe, J. H., & Bybee, K. A. (2009) · Clinical Cardiology · doi:10.1002/clc.20435 · Cited by 25
Metabolic Syndrome in Heart Failure
Arcopinto, M., Schiavo, A., Salzano, A., Bossone, E., D’Assante, R., Marsico, F., Rodríguez, P. D., Baliga, R. R., Cittadini, A., & Marra, A. M. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.02.004 · Cited by 25
An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability
Crouse, J. R. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.3.287 · Cited by 24
Pepine, C. J. (2010) · Annals of Medicine · doi:10.3109/07853890903260898 · Cited by 25
Hall, A. S., Jackson, B. M., Farrin, A. J., Efthymiou, M., Barth, J. H., Copeland, J., Bailey, K. M., Romaine, S. P. R., Balmforth, A. J., McCormack, T., et al. (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283316ce8 · Cited by 25
The Prognostic Value of Peripheral Artery Disease in Heart Failure: Insights from a Meta-analysis
Wei, B., Qian, C., Fang, Q., & Wang, Y. (2016) · Heart Lung and Circulation · doi:10.1016/j.hlc.2016.04.002 · Cited by 24
Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial
Butt, J. H., Jhund, P. S., Henderson, A. D., Claggett, B. L., Desai, A. S., Viswanathan, P., Kolkhof, P., Schloemer, P., Amarante, F., Lam, C. S. P., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00309-7 · Cited by 39
Self-citationFragasso, G., Stolfo, D., Anker, M. S., Bayés‐Genís, A., Chioncel, O. D., Heymans, S. R. B., Jhund, P. S., Lewis, B. S., Lopaschuk, G. D., Lund, L. H., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3703 · Cited by 38
Coenzyme Q10; an adjunctive therapy for congestive heart failure?
Molyneux, S. L., Florkowski, C. M., Richards, M., Lever, M., Young, J. M., & George, P. M. (2009) · PubMed · Cited by 24
Teramoto, T., Nakaya, N., Yokoyama, S., Ohashi, Y., Mizuno, K., & Nakamura, H. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.4176 · Cited by 24
Ridker, P. M., Rose, L. M., & Cook, N. R. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.12.028 · Cited by 25
Management of Dyslipidemias in the Presence of the Metabolic Syndrome or Type 2 Diabetes
Matikainen, N., & Taskinen, M. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0309-3 · Cited by 27
Swennen, M. H. J., Rutten, F. H., Kalkman, C. J., van der Graaf, Y., Sachs, A. P. E., & van der Heijden, G. J. M. G. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-002982 · Cited by 24
Pharmacology of heart failure: From basic science to novel therapies
Lother, A., & Hein, L. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.07.004 · Cited by 25
Cheng, Y., Qiao, L., Jiang, Z., Dong, X., Feng, H., Gui, Q., Lu, Y., & Liang, Y. (2020) · PubMed Central · Cited by 33
C-reactive protein and statins in heart failure with reduced and preserved ejection fraction
Park, J. J., Yoon, M., Cho, H.-W., Cho, H., Kim, K. H., Yang, D. H., Yoo, B., Kang, S., Baek, S. H., Jeon, E., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1064967 · Cited by 25
Coronary Artery Calcium Scanning Should be Used for Primary Prevention
Nasir, K., Shaw, L. J., Budoff, M. J., Ridker, P. M., & Peña, J. M. (2012) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2011.11.007 · Cited by 24
Smedt, R. H. E. D., Denig, P., Haaijer‐Ruskamp, F. M., & Jaarsma, T. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01954.x · Cited by 29
Heart Failure with Preserved Ejection Fraction in Older Adults
Chen, M. A. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.01.038 · Cited by 27
Statins and the Reduction of Sudden Cardiac Death: Antiarrhythmic or Anti-Ischemic Effect?
Beri, A., Contractor, T. A., Khasnis, A. A., & Thakur, R. K. (2010) · American Journal of Cardiovascular Drugs · doi:10.2165/11536690-000000000-00000 · Cited by 30
Galectin-3: clinical utility and prognostic value in patients with heart failure
Kramer, F. (2013) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s28562 · Cited by 26
“019).(48) Interestingly, patients with Gal-3 levels less than or equal to the median and NT-proBNP levels below 102.”
BackgroundBonsu, K. O., Kadirvelu, A., & Reidpath, D. D. (2013) · Systematic Reviews · doi:10.1186/2046-4053-2-22 · Cited by 28
Bhavnani, S. P., Coleman, C. I., White, C. M., Clyne, C. A., Yarlagadda, R. B., Guertin, D., & Kluger, J. (2008) · EP Europace · doi:10.1093/europace/eun128 · Cited by 25
A Review of the Role of Statins in Heart Failure Treatment
Niazi, M., Galehdar, N., Jamshidi, M., Mohammadi, R., & Moayyedkazemi, A. (2019) · Current Clinical Pharmacology · doi:10.2174/1574884714666190802125627 · Cited by 31
Cleland, J. G. F., Coletta, A. P., Abdellah, A. T., Cullington, D., Clark, A. L., & Rigby, A. S. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2007.12.004 · Cited by 24
Self-citationSeverely frail elderly patients do not need lipid-lowering drugs
Mallery, L. H., Moorhouse, P. A., McLean-Veysey, P. R., Allen, M., & Fleming, I. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84a.15114 · Cited by 28
Kostis, J. B., Giakoumis, M., Zinonos, S., Cabrera, J., & Kostis, W. J. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.01.020 · Cited by 25
Chun, K. J., & Jung, H. H. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2021.04.009 · Cited by 29
Haley, K. E., Almas, T., Shoar, S., Shaikh, S., Azhar, M., Cheema, F. H., & Hameed, A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112014 · Cited by 25
Impact of insulin therapy on the mortality of acute heart failure patients with diabetes mellitus
Jang, S. Y., Jang, J., Yang, D. H., Cho, H., Lim, S. K., Jeon, E., Lee, S. E., Kim, J., Kang, S., Baek, S. H., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01370-y · Cited by 23
Manejo do risco cardiovascular: dislipidemia
Izar, M. C. D. O., Fonseca, F. A. H., Faludi, A. Á., de Araújo, D. B., Valente, F., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-19 · Cited by 34
Pleiotropic Benefits of Statins in Cardiovascular Diseases
Wasim, R., Ansari, T. M., Ahsan, F., Siddiqui, M. H., Singh, A., Shariq, M., & Parveen, S. (2022) · Drug Research · doi:10.1055/a-1873-1978 · Cited by 29
Ennezat, P. V., Guerbaaï, R.-A., Maréchaux, S., Jemtel, T. H. L., & François, P. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001345 · Cited by 25
Use of Statins in Heart Failure with Preserved Ejection Fraction: Current Evidence and Perspectives
Ovchinnikov, A. G., Potekhina, A. V., Arefieva, T. I., Filatova, A. Y., Ageev, F. T., & Belyavskiy, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094958 · Cited by 31
Ma, T., Chang, M.-H., Tien, L., Liou, Y., & Jong, G. (2011) · Drugs & Aging · doi:10.2165/11597250-000000000-00000 · Cited by 24
Statin treatment for patients with heart failure
Tang, W. H. W., & Francis, G. S. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.29 · Cited by 24
How Common is Statin Use in the Oldest Old?
Thompson, W., Pottegård, A., Nielsen, J. B., Haastrup, P., & Jarbøl, D. E. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0567-x · Cited by 24
Maroo, B. P., Lavie, C. J., & Milani, R. V. (2008) · Drugs & Aging · doi:10.2165/00002512-200825080-00003 · Cited by 27
Sympathoinhibitory effect of statins in chronic heart failure
Gomes, M. E. R., Lenders, J. W. M., Bellersen, L., Verheugt, F. W. A., Smits, P., & Tack, C. J. (2009) · Clinical Autonomic Research · doi:10.1007/s10286-009-0041-2 · Cited by 23
Yoon, C., Youn, T., Ahn, S., Choi, D., Cho, G.-Y., Chae, I., Choi, J. M., Cho, H., Han, S., Cho, M., et al. (2012) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2011.12.006 · Cited by 24
When statin therapy stops: implications for the patient
Daskalopoulou, S. S. (2009) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32832ebf92 · Cited by 26
Ghafoury, R., Malek, M., Ismail‐Beigi, F., & Khamseh, M. E. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01743-6 · Cited by 31
Reverse epidemiology in different stages of heart failure
Güder, G., Gelbrich, G., Edelmann, F., Wachter, R., Pieske, B. M., Pankuweit, S., Maisch, B., Prettin, C., Brenner, S., Morbach, C., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.02.009 · Cited by 22
Traditional Heart Failure Medications and Sudden Cardiac Death Prevention: A Review
Chekakie, M. O. A. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413491496 · Cited by 23
“Treatment with rosuvastatin led to a decrease in hospitalization and was well tolerated by this population of patients.(144) The lack of benefit could be due to chance, short follow–up, or age of the population studied.”
BackgroundCharacteristics and treatment of hospitalized patients with CHF
Mareev, Y. V., & Mareev, V. Y. (2017) · Kardiologiia · doi:10.18087/cardio.2433 · Cited by 24
Self-citationTufaro, V., Serruys, P. W. J. C., Räber, L., Bennett, M. R., Torii, R., Gu, S. Z., Onuma, Y., Mathur, A., Baumbach, A., & Bourantas, C. V. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac051 · Cited by 23
Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?
Rossini, E., Biscetti, F., Rando, M. M., Nardella, E., Cecchini, A. L., Nicolazzi, M. A., Covino, M., Gasbarrini, A., Massetti, M., & Flex, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169326 · Cited by 31
Wołowiec, A., Wołowiec, Ł., Grześk, G., Jaśniak, A., Osiak, J., Husejko, J., & Kozakiewicz, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813723 · Cited by 25
Jiang, B. H., Tardif, J., Sauvageau, S., Ducharme, A., Shi, Y., Martin, J. G., & Dupuis, J. (2010) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2010.03.003 · Cited by 25
Rutishauser, J. (2011) · Swiss Medical Weekly · doi:10.4414/smw.2011.13310 · Cited by 23
Cleland, J. G. F., & Cullington, D. (2009) · Circulation Heart Failure · doi:10.1161/circheartfailure.109.859322 · Cited by 24
Self-citationCai, A., Li, X., Zhong, Q., Li, M., Wang, R., Liang, Y., Chen, W., Huang, T., Li, X., Zhou, Y., et al. (2016) · Medicine · doi:10.1097/md.0000000000003974 · Cited by 22
Metadata
- Authors
- Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., Gullestad, L., Hjalmarson, Å., Hradec, J., Jánosi, A., Kamenský, G., Komajda, M., Korewicki, J., Kuusi, T., Mach, F., Mareev, V., McMurray, J. J. V., Ranjith, N., Schaufelberger, M., Vanhaecke, J., van Veldhuisen, D. J., Waagstein, F., Wedel, H., & Wikstrand, J.
- Affiliations
- Oslo University Hospital (NO)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-29
- Volume
- 357
- Issue
- 22
- Pages
- 2248-2261
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2126452437
- Cited by
- 1,487
- References
- 27
- Citations by year
- 2026: 24 · 2025: 27 · 2024: 41 · 2023: 43 · 2022: 62 · 2021: 46 · 2020: 63 · 2019: 72 · 2018: 53 · 2017: 75 · 2016: 73 · 2015: 89 · 2014: 96 · 2013: 109 · 2012: 96
- FWCI
- 140.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.scopus.com
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- rosuvastatin, heart failure with reduced ejection fraction, elderly patients, statins, cardiovascular mortality, cardiovascular hospitalization, LDL cholesterol, high-sensitivity C-reactive protein, statin safety, myocardial infarction, stroke
- MeSH terms
- Rosuvastatin Calcium, Aged, Cardiovascular Diseases, Female, Fluorobenzenes, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Pyrimidines, Sulfonamides, Systole, Proportional Hazards Models, Single-Blind Method, Treatment Outcome, Myocardial Ischemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.